Open Trail of γIFN for Friedreich Ataxia
Open Trail of γIFN for Friedreich Ataxia
The investigator proposes an open label pilot study to investigate the safety and efficacy of
 gamma interferon (γIFN) in patients with Friedreich's Ataxia (FRDA). yIFN, an approved drug
 for treatment of granulomatous disease, has been shown to promote Frataxin expression in FRDA
 models in vitro and in vivo as well as in pilot human studies.

 Safety will monitored by clinical surveillance and biohumoral periodic assessment. Efficacy
 will be assessed by a combination of advanced neuroimaging techniques and established
 clinical indicators. The investigators intend to recruit over a 6 months period 12 subject
 with molecularly established FRDA. The protocol builds on a recently concluded observational
 study which established the pattern of clinical and neuroimaging abnormalities characterizing
 a cohort of patients with FA. The data already acquired through such study will constitute
 the T-6/-12 point, and together with T0 assessment, carried out at study entrance, will
 provide for each patient the exact appreciation of disease actual progression over a year
 time. Recruited patients will receive for 6 months yIFN at a final dose of 200 ug/three times
 a week. Patients will be evaluated clinically after 3 and 6 months (T3 and T6) of treatment
 and 6 months after treatment end (T+6) and by neuroimaging at T6 and T+6. The neuroimaging
 protocol, based on 3 Tesla scanner, consists in functional MRI, tractography. The clinical
 protocol consists on specific ataxia scales administration. Regular monitoring with for
 eventual adverse events will be provided. Frataxin levels in the peripheral blood mononuclear
 cells will also be evaluated at T0, T3, T6, T+6. Furthermore, the thickness of the cardiac
 ventricle and retinal nerve fibre layer (RNFL) thickness with optical coherence tomography
 (OCT) will be performed at T0, T6, T + 6.
Friedreich ataxia (FRDA) is a devastating neurodegenerative disease that affects children and
 young adults. Patients become progressively unable to coordinate movements and walking until
 severe disability ensues. Most patients develop dilated cardiomyopathy and congestive heart
 failure. The disease is non remissive and significantly shortens lifespan expectancy. FRDA is
 a genetic disease inherited in an autosomal recessive fashion. FRDA patients display abnormal
 GAA triplet expansions within the first intron of the frataxin gene that prevent proper gene
 expression. The levels of frataxin, a mitochondrial protein involved in iron metabolism and
 energy production, are insufficient and cells undergo prolonged stress and premature death.
 Mostly affected by frataxin deficiency are peripheral neurons of the dorsal root ganglia
 (DRG) and neurons of the cerebellar nucleus dentatus.

 FRDA affects 1 in 50,000 individuals in western countries and has no approved therapy. It has
 recently been shown that interferon gamma (γIFN), a natural regulator of the immune response
 and iron metabolism, stimulates frataxin gene transcription and promotes frataxin
 accumulation in cells, including frataxin-defective cells derived from FRDA patients.
 Moreover, prolonged treatment of YG8R mice, an animal model for FRDA, with γIFN results in
 accumulation of frataxin in DRG neurons and significantly prevents the deterioration of the
 sensorimotor performances of the mice over time.

 Since γIFN is also a drug available on the market as a recombinant protein (γIFN - 1b, TD
 Imukin® and Actimmune®), and already approved for two pediatric indications (malignant
 osteopetrosis and chronic granuloumatous disease), it could represent a quickly accessible
 therapeutic option for FRDA patients.

 A major obstacle to efficiently establish efficacy of treatment in FRDA is the lack of
 reliable and sensitive biomarkers. Clinical indicators (disease specific scales, timed
 performance tests) are prone to inter-rater variability and, above all, while valid and
 sensitive to long term changes, they are very inefficient in capturing changes in the short
 time interval (months) typically used in randomized clinical trials (RCTs).

 The advanced neuroimaging techniques such as Voxel-Based Morphometry (VBM), Susceptibility
 Weighted Imaging (SWI), Diffusion Tensor Imaging (DTI) and functional Magnetic Resonance
 Imaging (fMRI) could offer objective indicators of the disease progression that could serve
 as paraclinical end point in therapeutic trials. Surrogate end-points based on neuroimaging
 indicators have been extensively used in other neurological diseases such as Multiple
 Sclerosis, and their introduction speeded up significantly the recognition of effective
 treatments and their longitudinal evaluation.

 In the last years, in vivo MRI studies have provided information relative to the damage of
 cerebellar, cerebral and spinal cord areas involved in FRDA and other genetically determined
 ataxias, which could be useful to monitor disease progression.

 With the advent of the VBM, it is possible to quantify the degree of atrophy, to monitor it
 in time and to identify various pattern typical of a specific form of ataxia. Various studies
 have evidenced a significant correlation between the degree of the cerebellar atrophy, the
 severity of the clinical picture and also the duration of the disease .

 A pilot study conducted in a cohort of 9 FRDA affected adolescents who underwent a 6 month
 treatment with deferiprone, demonstrated a significant reduction in the mean R2* signal in
 the cerebellar dentate nuclei, an iron tissue store index. Modifications of the fMRI pattern
 in response to specific tasks involving both the motor and the planning ability have also
 been demonstrated in FRDA patients, and fMRI based protocols could offer an adjunctive
 indicator of disease progression or of therapy induced modification.

 Aims and purpose of the proposed investigation:

 -  Test safety of γIFN treatment given for 6 months at final dose of 200 mcg three times
 weekly in FRDA patients.

 -  Test the effect of γIFN treatment on disease specifc clinical scale (SARA)

 -  Test the effect of such treatment on a set of secondary imaging, laboratory and clinical
 end-points:

 -  fMRI changes in FRDA patients performing the finger tapping protocol

 -  DTI parameters

 -  Thickness of ventricular wall as measured by Ecocardiogram (EcoCG)

 -  Thickness of RNFL as measured by OCT

 -  Frataxin levels in cell lysates prepared from peripheral blood mononuclear cells
 (PBMC)

 -  Changes in quality of life and disability impact measure. What previous work is
 this project based on? Evidence for the possible efficacy of recombinant γIFN in
 FRDA has been gathered both in the animal model for the disease and in FRDA
 patients. In FRDA patients, a recently completed Phase II trial reported
 significant improvement on the FARS evaluation after 3 months treatment on a 100
 mcg, 3 times/weekly regimen. Moreover, another recently completed Phase II study
 suggests that the dosing of 200 mcg is reasonably well tolerated in FRDA patients.

 An articulated MRI protocol for FRDA patients aged 12-50 which included DTI, VBM, and fMRI
 following a selective motor paradigm has been tested, validated and implemented in the
 investigators Institute. By this protocol the investigators evaluated 22 FRDA patients and 15
 age and sex matched healthy controls, and found significant differences in DTI parameters (FA
 & MD) in the cerebellar white matter, long sensory and motor tracts, major commissural
 tracts, and in BOLD signal intensity and distribution of BOLD signal during performance of a
 finger tapping test. These latter disease specific changes were most evident in the
 ipsilateral cerebellar cortex. The observed changes correlated with the degree of
 neurological and functional impairment as measured with validated scales.

 These preliminary results indicate that DTI and fMRI changes may function as efficient
 surrogate end-points in RCT for FRDA patients.

 Design Open label pilot study. Primary safety end point: Safety of γIFN 6 month treatment at
 doses of 200 mcg 3 times a week Primary Efficacy end point: SARA score changes during the
 treatment period compared to those registered during the pre-treatment period and the
 post-treatment follow-up period

 Secondary end-points:

 o changes in: BOLD signal obtained during the selective motor task (finger tapping)

 -  DTI parameters (FA, MD) in the cerebellar white matter, the long and the commissural
 tracts

 -  Ventricular wall thickness (Eco CG)

 • RNFL thickness (OCT)

 -  Frataxin content in PBMC

 -  Changes in QoL measure (SF-36)

 -  Changes in Disability measure (WHO-DAS 2.0)

 Subjects

 Inclusion criteria:

 -  Molecularly defined FRDA,

 -  willingness to participate in the study and signing of the informed consent form.

 In order to control for the ongoing deterioration associated with the disease, the
 investigators will recruit only those patients who had been already studied with the MRI
 protocol and the functional scales indicated below 12 months before the beginning of the
 present study.

 Exclusion criteria:

 -  presence of any contraindication for MRI study,

 -  presence of clinically significant heart, liver or kidney disease or other medically
 unstable conditions.

 -  Known sensitivity to γIFN.

 -  Previous exposure to recombinant hematopoietin.

 -  Ongoing use of desferiprone or other specific FRDA treatmenent

 -  pregnancy or lactation

 Study drug γIFN (Imukin 100 mcg/vial)

 Treatment will be:

 1. st two weeks: 100 mcg/three times a week From the 3rd week: 200 mcg three times a week
 for the following 22 weeks

 Imaging protocol

 The MRI examination will be administered at 4 T points:

 - T-12 to -6: for this point the data already stored along in the last year from the
 published invesitgators' MRI study on 18 subjects will be used

 - T0: at time of recruitment

 - T6: after 6 months of treatment

 - T+6: 6 months after treatment termination The protocol will be acquired on a 3 T
 scanner equipped with a 32-channel head coil and will include morphological, structural
 (DTI) and functional (fMRI) sequences.

 A 3D T1-weighted TFE sequence (TR/TE=8.2/3.7, voxel size= 1x1x1 mm, 150 slices) will be
 acquired in order to obtain morphological data suitable for volumetric analysis for
 voxel-based morphometry.

 The DTI data will be acquired by means of a T2-weighted EPI sequence (voxel size
 =2.5x2.5x2.5 mm) along 32 non-collinear directions, with multiple b-values (0, 300, 1100
 sec/mm2) and will be evaluated off-line with the Tortoise dedicated software. Functional
 data will be acquired by means of a T2-weighted EPI sequence (TR/TE=2000/20,
 thickness=2.5mm, 40 slices) covering the whole brain and cerebellum.

 Functional images will be acquired during a task that implies manual coordination and
 precision, in order to test possible effect of the treatment over the functional
 organization of motor networks.

 Laboratory protocol Eco CG study will be performed at T0, T6, T+6 with established
 protocol. Frataxin levels monitoring will be performed at T0, T3 (after 3 months) and T6
 (after 6 months).

 Clinical measures and Safety monitoring A trained neurologist will visit each patient at
 T0, T3, T6 and T+6 and report all vital signs and register other objective findings
 including adverse event (AE).

 A detailed checklist with all the known AE reported with γIFN treatment will be
 presented to each participant at T0, T3, T6.

 The following blood test will be performed at T0, T3, T6 :

 -Cell Blood Count, Erythrocyte Sedimentation Rate, Ca2+, Cl-, Na+, Mg2+, K+, Albumin,
 Globulins, Glucose, Blood Urea Nitrogen, Uric Acid, Creatinine, Aspartate Transaminase,
 Alanine Transaminase, Iron, Ferritin, Transferrin

 Statistical analysis For the MRI protocol, each dataset will be processed with a
 dedicated pipeline and appropriate software.

 The T1 volumes will be processed following the standard FMRIB Software Library (FSL)
 pipeline and performing VBM. As first step a study specific template of gray matter,
 using the routine "buildtemplateparallel" of Advanced Normalization Tools (ANTs), that
 performs an iterative template construction with elastic transformations will be
 created.

 The DTI data will be corrected for eddy currents and motion artefacts and then the
 diffusion tensor will be computed using the non-linear mono-exponential diffusion model,
 obtaining maps of "fractional anisotropy" (FA), "mean diffusivity" (MD), "radial
 diffusivity" (RD) and "axial diffusivity" (AD).

 To quantify the statistical differences over time, the diffusion data of all subjects
 will be moved to a common space through rigid, affine and diffeomorphic registrations
 based on the diffusion tensor itself. Using the transformations computed on the tensors,
 3 different tests will be performed:

 - Tract Based Spatial Statistics (TBSS);

 - Voxel-wise statistical analysis based on permutations;

 - Statistical analysis of regions of interest (ROI) with generalized linear models
 (GLM).

 The fMRI data will be processed using Statistical Parametric Mapping 8 (SPM8). A
 first-level Fixed Effect analysis will be performed on each subject using global linear
 model and motion parameters as confounds. For the group-level analysis a Random Effect
 Analysis with contrasts obtained in the single subject step analysis will be performed.
 A two sample t-test will finally be computed to check differences in activations over
 time.

 All time-dependent data (including ROI-wise neuroimaging results) will be analyzed using
 multivariate linear mixed models, including timepoints as a repeated within-subject
 factor and included sex, age at onset, disease duration, years of education and number
 of GAA1 repeats within the smaller FXN allele as covariates of no interest. N case of a
 statistically significant (p<0.05) overall effect of time, pairwise comparisons between
 timepoints will be performed and corrected for multiple comparisons across pairs of
 timepoints. Correlation analysis will also be performed between possible modifications
 in SARA scores between consecutive time-points and the respective changes in the MRI
 derived structural and functional measures.

 References (Research Project):

 - Akhlaghi H, Yu J, Corben L, Georgiou-Karistianis N, Bradshaw JL, Storey E, Delatycki
 MB, Egan GF. Cognitive Deficits In Friedreich Ataxia Correlate with Micro-structural
 Changes in Dentatorubral Tract. Cerebellum. 2013 Oct 2.

 - Akhlaghi H, Corben L, Georgiou-Karistianis N, Bradshaw J, Delatycki MB, Storey E, Egan
 GF. A functional MRI study of motor dysfunction in Friedreich's ataxia. Brain Res. 2012
 Aug 30;1471:138-54.

 - Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D,
 Thalabard JC, Munnich A, Cabantchik ZI. Selective iron chelation in Friedreich ataxia:
 biologic and clinical implications. Blood. 2007 Jul 1;110(1):401-8.

 - Della Nave R, Ginestroni A, Tessa C, Salvatore E, Bartolomei I, Salvi F, Dotti MT, De
 Michele G, Piacentini S, Mascalchi M. Brain white matter tracts degeneration in
 Friedreich ataxia. An in vivo MRI study using tract-based spatial statistics and
 voxel-based morphometry.Neuroimage. 2008a Mar 1;40(1):19-25.

 - Della Nave R, Ginestroni A, Tessa C, Cosottini M, Giannelli M, Salvatore E, Sartucci
 F, De Michele G, Dotti MT, Piacentini S, Mascalchi M. Brain structural damage in
 spinocerebellar ataxia type 2. A voxel-based morphometry study. Mov Disord. 2008b Apr
 30;23(6):899-903. doi: 10.1002/mds.21982.

 - Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose
 idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
 Lancet Neurol. 2007 Oct;6(10):878-86.

 - Georgiou-Karistianis N, Akhlaghi H, Corben LA, Delatycki MB, Storey E, Bradshaw JL,
 Egan GF. Decreased functional brain activation in Friedreich ataxia using the Simon
 effect task. Brain and Cognition 79 (2012) 200-208.

 - Jayakumar PN, Desai S, Pal PK, Balivada S, Ellika S, Kalladka D. Functional correlates
 of incoordination in patients with spinocerebellar ataxia 1: a preliminary fMRI study. J
 Clin Neurosci. 2008 Mar;15(3):269-77. doi: 10.1016/j.jocn.2007.06.021. Epub 2008 Jan 10.

 - Mantovan MC, Martinuzzi A, Squarzanti F, Bolla A, Silvestri I, Liessi G, Macchi C,
 Ruzza G, Trevisan CP, Angelini C. Exploring mental status in Friedreich's ataxia: a
 combined neuropsychological, behavioral and neuroimaging study. Eur J Neurol. 2006
 Aug;13(8):827-35.

 - Montermini L, Richter A, Morgan K, Justice CM, Julien D, Castellotti B, Mercier J,
 Poirier J, Capozzoli F, Bouchard JP, Lemieux B, Mathieu J, Vanasse M, Seni MH, Graham G,
 Andermann F, Andermann E, Melançon SB, Keats BJ, Di Donato S, Pandolfo M (1997)
 Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat
 expansion. Ann Neurol 41:675-682.

 - Ormerod IE, Harding AE, Miller DH, Johnson G, MacManus D, du Boulay EP, Kendall BE,
 Moseley IF, McDonald WI. Magnetic resonance imaging in degenerative ataxic disorders.

 - J Neurol Neurosurg Psychiatry. 1994 Jan;57(1):51-7. Review.

 - Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV. MRI estimates of brain iron
 concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI)
 methods. Neuroimage. 2009 Aug 15;47(2):493-500.

 - Pierpaoli C, Walker L, Irfanoglu MO, Barnett A, Basser P, Chang L-C, Koay C, Pajevic
 S, Rohde G, Sarlls J, and Wu M. 2010, TORTOISE: an integrated software package for
 processing of diffusion MRI data, ISMRM 18th annual meeting, Stockholm, Sweden, #1597

 - Prakash N, Hageman N, Hua X, Toga AW, Perlman SL, Salamon N. Patterns of fractional
 anisotropy changes in white matter of cerebellar peduncles distinguish spinocerebellar
 ataxia-1 from multiple system atrophy and other ataxia syndromes. Neuroimage. 2009
 Aug;47 Suppl 2:T72-81. doi: 10.1016/j.neuroimage.2009.05.013. Epub 2009 May 14.

 - Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth
 of a biomarker? NMR Biomed. 2004 Nov;17(7):433-45. Review.

 - Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P,
 Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M,
 Ribai P, Rola R, Schöls L, Szymanski S, van de Warrenburg BP, Dürr A, Klockgether T,
 Fancellu R. Scale for the assessment and rating of ataxia: development of a new clinical
 scale. Neurology. 2006 Jun 13;66(11):1717-20.

 - Schulz JB, Dehmer T, Schöls L, Mende H, Hardt C, Vorgerd M, Bürk K, Matson W, Dichgans
 J, Beal MF, Bogdanov MB. Oxidative stress in patients with Friedreich ataxia. Neurology.
 2000 Dec 12;55(11):1719-21.

 - Seyer L, Greeley N, Foerster D et al. Open label study of Interferon gamma 1b (IFN-γ)
 in Friedreich ataxia. Acta Neurologica Scandinavica 2014 Oct 21. doi: 10.1111/ane.12337

 - Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a
 meta-analysis of randomised trials. Lancet Neurol. 2013 Jul;12(7):669-76. doi:
 10.1016/S1474-4422(13)70103-0.

 - Stankiewicz J, Panter SS, Neema M, Arora A, Batt CE, Bakshi R. Iron in chronic brain
 disorders: imaging and neurotherapeutic implications. Neurotherapeutics. 2007
 Jul;4(3):371-86.

 - Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, Taylor P, Wilson R,
 Ashizawa T; Cooperative Ataxia Group. Measuring Friedreich ataxia: Interrater
 reliability of a neurologic rating scale. Neurology. 2005 Apr 12;64(7):1261-2.

 -  Tai G, Corben LA, Gurrin L et al. A study of up to 12 years of follow-up of
 Friedreich ataxia utilizing four measurement tools. JNNP 2014, Aug 11 as
 10.1136/jnnp-2014-308022

 -  Tomassini, B., Arcuri, G., Fortuni, S., Sandi, C., Ezzatizadeh, V., Casali, C.,
 Condo, I., Malisan, F., Al-Mahdawi, S., Pook, M. and Testi R. (2012) Interferon
 gamma upregulates frataxin and corrects the functional deficits in a Friedreich
 ataxia model. Hum Mol Genet, 21, 2855-2861.

 -  Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A,
 Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A,
 Schut L, Timann D, Honnorat J, Nighoghossian N, Manyam B. International Cooperative
 Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The
 Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol
 Sci. 1997 Feb 12;145(2):205-11.

 -  Velasco-Sánchez D, Aracil A, Montero R, Mas A, Jiménez L, O'Callaghan M, Tondo M,
 Capdevila A, Blanch J, Artuch R, Pineda M. Combined therapy with idebenone and
 deferiprone in patients with Friedreich's ataxia. Cerebellum. 2011 Mar;10(1):1-8.

 -  Villanueva-Haba V, Garcés-Sánchez M, Bataller L, Palau F, Vílchez J. Neuroimaging
 study with morphometric analysis of hereditary and idiopathic ataxia. Neurologia.
 2001 Mar;16(3):105-11.

 -  TORTOISE https://science.nichd.nih.gov/confluence/display/nihpd/TORTOISE
Inclusion criteria:

 -  Molecularly defined FRDA,

 -  willingness to participate in the study and signing of the informed consent form.

 -  In order to control for the ongoing deterioration associated with the disease, the
 investigator will recruit only those patients who had been already studied with the
 MRI protocol and the functional scales indicated below approxymately 12 months before
 the beginning of the present study.

 Exclusion Criteria:

 -  presence of any contraindication for MRI study,

 -  presence of clinically significant heart, liver or kidney disease or other medically
 unstable conditions.

 -  Known sensitivity to γIFN.

 -  Previous exposure to recombinant hematopoietin.

 -  Ongoing use of desferiprone or other specific FRDA treatments.

 -  Pregnancy or lactation